tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
RatingsAgios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
10h ago
AGIO
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
1d ago
AGIO
Morning Movers: Equifax sinks following second quarter earnings
PremiumThe Fly
Morning Movers: Equifax sinks following second quarter earnings
1d ago
GM
DHI
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
1d ago
AGIO
Agios Pharmaceuticals announces topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals announces topline results from tebapivat trial
1d ago
AGIO
Agios Pharmaceuticals rises 13.5%
PremiumThe FlyAgios Pharmaceuticals rises 13.5%
15d ago
AGIO
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
Premium
Ratings
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
15d ago
AGIO
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
Premium
The Fly
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
15d ago
AGIO
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
PremiumThe Fly
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
15d ago
AGIO
Agios Pharmaceuticals rises 12.9%
PremiumThe Fly
Agios Pharmaceuticals rises 12.9%
15d ago
AGIO
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
15d ago
AGIO
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
15d ago
AGIO
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
PremiumThe FlyAgios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
15d ago
AGIO
Agios Pharmaceuticals granted priority review for mitapivat sNDA
Premium
The Fly
Agios Pharmaceuticals granted priority review for mitapivat sNDA
15d ago
AGIO
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
Premium
Company Announcements
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
1M ago
8K
AGIO
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
PremiumCompany Announcements
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
1M ago
AGIO
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
PremiumRatings
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
1M ago
AGIO
Emily Bodnar Reiterates Buy on Agios, Citing Strong Mitapivat SCD Profile and Raising Price Target to $54
PremiumRatings
Emily Bodnar Reiterates Buy on Agios, Citing Strong Mitapivat SCD Profile and Raising Price Target to $54
1M ago
AGIO
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
1M ago
AGIO
Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat
PremiumThe FlyAgios Pharmaceuticals presented results from Phase 3 trial of mitapivat
1M ago
AGIO
Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan
Premium
The Fly
Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan
1M ago
AGIO
Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
Premium
Ratings
Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed
2M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >